The NCT02947893 is a phase 2 study with forty-two participants, testing the efficacy of Nilotinib on CSF levels of Abeta40/42, total Tau and p-Tau231/181, which is against the mild to moderate dementia due to AD. Here, MAPT is linked to Alzheimer disease.